{"filings":[{"id":471359,"accession_number":"0001213900-26-057811","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2026-05-15T20:20:52+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Aditxt implements 1-for-27 reverse stock split effective May 18, 2026 for Nasdaq compliance","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio 1-for-27; effective 4:01 p.m. ET May 15; trading on split-adjusted basis from May 18.","Shares outstanding will reduce from ~13,773,321 to ~510,123 post-split.","No change in authorized shares or par value; fractional shares rounded up to next whole share.","Outstanding warrants and stock options adjusted proportionally in exercise price and shares.","Primary goal: meet Nasdaq minimum bid price requirement; CUSIP changes to 007025869."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95032,"accession_number":"0001213900-26-053904","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Aditxt receives Nasdaq delisting notice for bid price non-compliance; to appeal","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Staff Determination on May 6, 2026 for closing bid price below $1 for 30 consecutive business days (March 24–May 5, 2026).","Company ineligible for 180-day cure period due to prior reverse stock splits with cumulative ratio of 250+ to one over prior two years.","Aditxt intends to request a hearing before Nasdaq Hearings Panel to appeal; delisting stayed during hearing process.","No assurance of success in appeal or ability to regain compliance with Nasdaq listing requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95031,"accession_number":"0001213900-26-050995","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aditxt shareholders approve reverse stock split authorization up to 1:250","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected; Amro Albanna received 122,066 votes for.","Advisory 'say-on-pay' approved with 117,998 for, 26,096 against; board opts for every-three-years frequency.","Ratification of dbbmckennon as auditor passed with 264,043 votes for, 18,229 against.","Reverse split authorization approved (205,568 for, 84,351 against); board can set ratio from 1:2 to 1:250 within one year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95030,"accession_number":"0001213900-26-043227","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Aditxt issues $1.25M senior notes at 10% due Sept 2026; net proceeds $1M after OID","event_type":"debt","confidence":"high","bullets":["Note principal $1.25M, purchase price $1M, original issue discount $250K; interest 10% payable monthly.","Matures Sept 30, 2026; 100% of gross proceeds from ATM/equity line sales must redeem notes at 120% weekly.","Company may redeem all notes at 120%; default triggers holder redemption at 125%; bankruptcy requires immediate 125% payment.","Seven Knots, LLC granted holdback right to directly distribute equity line/ATM proceeds to noteholders until repayment.","Negative covenants post-maturity restrict indebtedness, liens, dividends, asset transfers, and acceleration of other debt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95028,"accession_number":"0001213900-26-041018","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K/A","filed_at":"2026-04-07T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Aditxt acquisition target Ignite shows $5.7M net loss, going concern doubt","event_type":"m_and_a","confidence":"high","bullets":["Ignite incurred net loss of $5.7M for 2025; revenue was only $43.5K (down from $72K in 2024).","Ignite recorded $748K impairment on lab equipment due to minimal cash flows from use.","Auditors expressed substantial doubt about Ignite's ability to continue as going concern.","Aditxt issued 36,000 shares of Series A-2 Convertible Preferred Stock ($36M stated value) for Ignite.","Intercompany payables to former member IMAC totaled $4.6M at December 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95029,"accession_number":"0001213900-26-038906","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Aditxt regains Nasdaq compliance following equity restoration to $3.95M","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Aditxt on April 1, 2026, that it now complies with Listing Rule 5550(b)(1).","Stockholders' equity of $3,953,682 was evidenced by the March 31, 2026, Form 10-K.","The earlier deficiency notice from December 1, 2025, is now formally closed.","Aditxt avoided potential delisting from The Nasdaq Stock Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107809,"accession_number":"0001213900-26-035973","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aditxt increases ATM equity offering by $36.8M to up to $53.4M","event_type":"other_material","confidence":"high","bullets":["Maximum aggregate offering price increased by $36.8M to $53,398,964 under existing ATM agreement.","Approximately $21.3M in shares have already been sold under the same agreement to date.","ATM facility with H.C. Wainwright & Co. originally dated October 25, 2024.","Prospectus supplement filed concurrently with the increase.","Shares sold will be common stock, par value $0.001 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107808,"accession_number":"0001213900-26-027281","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["1.01","5.03","2.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Aditxt acquires Ignite Proteomics for $36M in preferred stock; issues $3.2M notes","event_type":"m_and_a","confidence":"high","bullets":["Acquired 100% of Ignite Proteomics for 36,000 Series A-2 Convertible Preferred Shares (stated value $36M).","Ignite's RPPA platform measures protein expression for therapy selection; CLIA lab, Medicare PLA ~$2,200/test.","Closed $3.2M note purchase (10% OID) with $2.875M funding; 6% interest, 9-month maturity, prepayable.","Company believes it regained compliance with Nasdaq minimum stockholders' equity requirement ($2.5M) after acquisition.","Ignite plans to launch program in 2026 targeting >600,000 US metastatic cancer patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107807,"accession_number":"0001213900-26-023888","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Aditxt announces 1-for-8 reverse stock split effective March 6 for Nasdaq compliance","event_type":"other_material","confidence":"high","bullets":["Reverse split at 1-for-8 ratio, effective 4:01 p.m. ET March 6, 2026; split-adjusted trading begins March 9.","Post-split shares outstanding approx. 517,856; fractional shares rounded up to next whole share.","Adjustments to exercise prices and share counts for outstanding warrants and stock options.","Split approved by stockholders on Feb 13, 2026; board set ratio; new CUSIP 007025877; symbol ADTX unchanged.","Primary purpose: regain compliance with Nasdaq minimum bid price requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107806,"accession_number":"0001213900-26-016565","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aditxt shareholders approve name change to bitXbio, Inc. and reverse stock split authorization","event_type":"other","confidence":"high","bullets":["Shareholders approved name change to bitXbio, Inc. (455,456 for, 40,462 against).","Authorized reverse stock split ratio between 1:5 and 1:250, board discretion within one year.","Approved increase of 2021 Omnibus Plan shares from 3 to 350,000 (147,125 for).","Approved 2025 Employee Stock Purchase Plan (158,645 for).","Approved issuance of shares underlying Series A-1, Series C-1, and July warrants for Nasdaq compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107805,"accession_number":"0001213900-26-010217","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Aditxt adjourns special meeting to Feb 13 for reverse split, name change, equity plan votes","event_type":"other_material","confidence":"high","bullets":["Special meeting adjourned to Feb 13, 2026 at 12 PM ET to allow more stockholder voting time.","Proposals include approval of shares issuance under Series A-1 and C-1 convertible preferred and warrants from 2023-2024.","Stockholders to vote on 2025 ESPP and amendment to 2021 Omnibus Plan to increase authorized shares from 3 to 350,000.","Non-binding advisory vote on corporate name change from Aditxt to bitXbio, Inc.","Board seeks authority for reverse stock split at ratio between 1:5 and 1:250, effective within one year of approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107804,"accession_number":"0001213900-26-008539","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Aditxt gets Nasdaq extension to regain compliance with $2.5M equity rule","event_type":"regulatory","confidence":"high","bullets":["Extension granted Jan 27, 2026; must complete financing and file compliance report by May 15, 2026.","Nasdaq requires minimum $2.5M stockholders' equity, $35M market value of listed securities, or $500K net income.","If compliance not shown by June 30, 2026 periodic filing, delisting may follow; appeal rights available.","Company warns it may not regain or maintain compliance; forward-looking statements included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124209,"accession_number":"0001213900-25-118750","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Aditxt receives Nasdaq delisting notice for insufficient stockholders' equity","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Aditxt on Dec 1, 2025, that it fails to meet minimum $2.5M stockholders' equity requirement.","Company must submit a compliance plan by Jan 15, 2026; if accepted, extension to May 30, 2026.","Failure to regain compliance may result in delisting of common stock (ADTX) from Nasdaq.","Company may appeal any delisting decision to a Nasdaq hearings panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124208,"accession_number":"0001213900-25-111790","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aditxt files preliminary proxy for name change to bitXbio and ESPP; outlines digital asset treasury strategy","event_type":"other_material","confidence":"medium","bullets":["Filed preliminary proxy for special meeting seeking approval of ESPP and non-binding advisory vote on name change to bitXbio, Inc.","Plans to create a Digital Asset Treasury comprising crypto reserve, utility token, and tokenized venture representations; no digital asset investments made to date.","Pearsanta subsidiary announces planned IPO in 2026, subject to market conditions; Evofem focuses on regaining national exchange listing.","bitXbio strategy aims to connect public markets, blockchain/Web3, and life sciences through a participation-driven model.","Company currently holds no digital assets; any DAT implementation will depend on available funds and market conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124207,"accession_number":"0001213900-25-104704","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2025-10-31T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Aditxt announces 1-for-113 reverse stock split effective Nov 3, 2025 to regain Nasdaq compliance","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio set at 1-for-113; effective at 4:01 p.m. ET Oct 31, trading begins split-adjusted Nov 3.","Post-split shares outstanding will be approximately 501,401; fractional shares rounded up to next whole share.","Primary purpose is to cure Nasdaq minimum bid price deficiency; CUSIP changes to 007025885.","No change in authorized shares or par value; proportionate adjustments made to options, warrants, and RSUs.","Stockholders holding through brokers need no action; record holders will receive details from transfer agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124206,"accession_number":"0001213900-25-100380","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Aditxt merger with Evofem terminated after shareholder vote fails, end date passes","event_type":"m_and_a","confidence":"high","bullets":["Evofem terminated the Merger Agreement effective Oct 20, 2025, citing Section 8.1(b)(ii) (end date passed) and 8.1(b)(iv) (failure to obtain shareholder approval at the special meeting).","No termination fee or early-termination penalty is payable by Aditxt in connection with this termination.","Aditxt is reviewing the notice and evaluating its rights and remedies under the Merger Agreement and applicable law.","Certain provisions survive termination, including the parties' Non-Disclosure Agreement dated Oct 23, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124205,"accession_number":"0001213900-25-095840","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Aditxt hires Christopher J. Porcelli as GC, Chief People Officer and Corporate Secretary","event_type":"leadership","confidence":"high","bullets":["Porcelli will receive $350,000 annual base salary and eligibility for senior executive benefit plans.","Initial equity award subject to Compensation Committee approval, vesting over three years.","Employment is at-will, effective September 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140874,"accession_number":"0001213900-25-091128","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2025-09-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aditxt shareholders approve reverse stock split authorization up to 1:250","event_type":"other_material","confidence":"high","bullets":["Reverse split authorization passed: 1,178,583 For, 473,001 Against, 13,596 Abstain.","Board granted discretion to set ratio between 1:5 and 1:250, effective within one year.","All five director nominees re-elected: Albanna, Shabahang, Brady, Nelson, Hermina.","Ratification of dbb mckennon as independent auditor: 1,506,751 For, 92,439 Against.","Quorum of 33.59% of voting authority at reconvened annual meeting on Sept 23, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140873,"accession_number":"0001213900-25-088210","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Aditxt issues $212.5K senior notes at 10% OID, adjourns annual meeting for reverse split vote","event_type":"debt","confidence":"high","bullets":["Issued senior unsecured notes: $212,500 principal for $170,000 (20% OID), 10% interest, matures Sept 30, 2025.","All gross proceeds from future ATM/equity-line stock sales must be used to repay the notes.","Annual meeting adjourned to Sept 23, 2025 for votes on board, auditor, and reverse stock split (1:5 to 1:250).","Notes include events of default: trading suspension, payment failure, bankruptcy, and $500K+ debt defaults."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140872,"accession_number":"0001213900-25-081146","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aditxt, Evofem amend merger agreement; adds Series G-1 preferred, new closing conditions","event_type":"m_and_a","confidence":"high","bullets":["Amendment No. 6 adds Evofem Series G-1 Preferred Stock to the definition of Unconverted Company Preferred Stock.","New condition: Aditxt must receive waivers from each holder of Evofem Series E-1 Convertible Preferred Stock.","Dissenting shares threshold set: no more than 5,932,818 common shares or 202 preferred shares.","Exchange Agreements limited to 89,021 shares of Aditxt preferred stock from Evofem convertible noteholders.","Exhibit C replaced with Certificate of Designation for new Series A-2 Convertible Preferred Stock of Aditxt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140865,"accession_number":"0001213900-25-077698","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K/A","filed_at":"2025-08-18T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Aditxt files amended 8-K with Evofem unaudited interim financials for H1 2025","event_type":"other_material","confidence":"high","bullets":["Evofem H1 2025 revenue $5.67M, net loss $0.83M (unaudited).","Pro forma combined net loss of $15.99M for six months ended June 30, 2025.","Acquisition consideration: $116.5M total ($99.1M convertible preferred, $1.8M cash, $15.7M notes).","Preliminary goodwill $134.6M; intangible asset (SOLOSEC) $4.7M with 16-year life.","Merger consummation extended to Sept 30, 2025 per Fifth Amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140871,"accession_number":"0001213900-25-074330","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CEO presents Pearsanta IPO plans; commercialization target Q1 2026","event_type":"other_material","confidence":"medium","bullets":["CEO Amro Albanna presented at Wall Street Reporter livestream; discussed Pearsanta IPO plans.","Pearsanta's cancer diagnostics platform uses mitochondrial DNA blood tests; initial targets prostate cancer and endometriosis.","Commercial launch of first tests targeted for end of 2025 / Q1 2026 after validation studies.","Pearsanta IPO planned for early first half 2026 with Spartan Capital as underwriter.","Aditxt strategy: acquire health innovations, build in-house, monetize via events like Pearsanta IPO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140870,"accession_number":"0001213900-25-073670","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["5.02","5.08"],"status":"ready","headline":"Aditxt board members Runge and Pelletier will not stand for reelection; annual meeting set for Sept 16, 2025","event_type":"other_material","confidence":"high","bullets":["Jeffrey Runge not seeking reelection at 2025 Annual Meeting; will serve until term ends.","Saundra Pelletier not seeking reelection; per Evofem merger agreement, she will join board and be President of Adifem after closing.","Board size to reduce from 7 to 5 after 2025 Annual Meeting.","2025 Annual Meeting scheduled for September 16, 2025; record date August 8, 2025.","Deadline for stockholder proposals/nominations is August 18, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140869,"accession_number":"0001213900-25-067130","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aditxt CEO presents autoimmunity unit Adimune; stock at $5M market cap","event_type":"other_material","confidence":"high","bullets":["CEO presented at Wall Street Reporter livestream on July 22, 2025, focusing on subsidiary Adimune.","Adimune aims to reprogram immune system for autoimmune diseases; currently preclinical with human trials as key catalyst.","Other catalysts: Pearsanta cancer detection spin-off IPO and Adifem (Evofem) acquisition close expected Sept 2025.","CEO believes stock's ~$5M market cap is disconnected from value proposition; multiple shots on goal.","Adimune approach contrasts with traditional immunosuppressants; results from human trials awaited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140868,"accession_number":"0001213900-25-066145","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aditxt subsidiary Pearsanta targets prostate cancer test launch by end-2025; IPO spin-off planned","event_type":"other","confidence":"medium","bullets":["Pearsanta plans to launch a lab-developed test for prostate cancer using mitochondrial DNA detection by end of 2025.","CEO Amro Albanna stated 70% of cancer deaths could be prevented if caught early; Pearsanta aims for early detection via non-invasive blood test.","Aditxt plans to spin off Pearsanta via IPO, retaining ~60% ownership; values Aditxt's stake potentially at $60M vs. current $5M market cap.","The test will initially run at CLIA/CAP lab in Richmond, VA; FDA submission for kit development planned later.","Other subsidiaries highlighted: Adimune (autoimmunity) and pending Adifem/Evofem acquisition (women's health) expected to close by September 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140867,"accession_number":"0001213900-25-062807","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aditxt CEO presents at investor event; updates on Evofem close, Pearsanta commercialization, crypto strategy","event_type":"other_material","confidence":"high","bullets":["CEO Amro Albanna presented at Wall Street Reporter's Next Super Stock livestream on July 8, 2025, discussing business model as 'publicly owned innovation accelerator'.","Pearsanta validation ongoing; expects to commercialize prostate cancer and endometriosis tests by Q1 2026.","Evofem acquisition (women's health) expected to close by end of September 2025, subject to financing, as anchor for Adifem.","Announced Bitcoin/crypto treasury strategy to broaden shareholder base; market cap ~$5M.","Adimune plans to file for human trials Q4 2025/Q1 2026 for stiff person syndrome, type 1 diabetes, psoriasis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140866,"accession_number":"0001213900-25-060391","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Aditxt raises $1M in senior notes, invests $925K in Evofem; CEO targets Evofem close by Sept 2025","event_type":"other_material","confidence":"high","bullets":["Issued $1M senior notes (10% interest, maturity Sept 30, 2025) at $800K purchase price (20% original issue discount).","Purchased $1.42M Evofem convertible note and warrant for $925K; convertible at $0.0154/share, warrant exercisable for 5 years.","Evofem reported ~$20M revenue in 2024; CEO says pending acquisition target close by end of September 2025, subject to shareholder approval.","Pearsanta near commercialization (end 2025/Q1 2026) for prostate cancer and endometriosis tests using mitochondrial DNA.","Adimune autoimmune therapeutic platform still early stage; described as 'sleeping giant'; retraining immune system approach."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158622,"accession_number":"0001213900-25-057831","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Aditxt receives $190K insider loans from CEO and CInO; issues 600K-share warrant to consultant","event_type":"other_material","confidence":"high","bullets":["CEO Amro Albanna loaned $90,000 and CInO Shahrokh Shabahang loaned $100,000 at 7.5% interest, due July 20, 2025.","Company issued warrant for 600,000 shares at $2.00 exercise price to a consultant for investor marketing services.","Loans and warrant were issued in reliance on Section 4(a)(2) exemption from registration.","Marketing services agreement entered on June 24, 2025 with a consultant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158621,"accession_number":"0001213900-25-052635","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["1.01","2.03","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Aditxt appoints Evofem CEO Saundra Pelletier to board; officer loans $70K","event_type":"leadership","confidence":"high","bullets":["Board appoints Saundra Pelletier (CEO of Evofem) as director, effective June 5, 2025.","Chief Innovation Officer Shahrokh Shabahang loans $70,000 at 7.5%, due Dec 5, 2025.","Weekly update: Adimune targets Q4 2025 regulatory submission for ADI-100 autoimmune therapy.","Evofem generated $20M net revenue in 2024; CEO cites capital dependency for growth.","Pending Evofem merger extended to Sept 30, 2025; capital needed for milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158620,"accession_number":"0001213900-25-050060","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aditxt reiterates Sept 2025 close target for Evofem deal; Evofem had $19.5M revenue, first ex-US deal signed","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of Evofem targeted to close by September 2025; conditions include resolving senior creditor and Evofem shareholder vote.","Evofem generated $19.5M net revenue last year; has two FDA-approved products (Phexxi, Solosec) and signed first ex-US deal with Pharma 1 in Middle East.","New manufacturer Lee Pharma committed to lowering Evofem's COGS by over 50% to mitigate tariff volatility and support European expansion.","Pearsanta's endometriosis/ovarian cancer diagnostic platform expected near revenue in Q4 2025; Adimune autoimmune program targets regulatory filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158619,"accession_number":"0001213900-25-047519","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"CEO Amro Albanna lends $233K to Aditxt via unsecured note due Nov 2025","event_type":"debt","confidence":"high","bullets":["Amro Albanna, CEO, provided $233,000 unsecured loan to Aditxt on May 22, 2025.","Interest accrues at 7.5% per annum (Prime rate); principal and interest due Nov 22, 2025.","Loan is unsecured and may be prepaid; event of default accelerates payment.","Note issued as related-party transaction; company relied on Section 4(a)(2) exemption.","Proceeds provide short-term working capital; loan represents insider support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158618,"accession_number":"0001213900-25-045478","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aditxt Q3 plan: simplify cap table, cut debt, advance Adimune and Pearsanta","event_type":"other_material","confidence":"medium","bullets":["CEO states goal is transition from speculative to growth stage by end of Q3 2025.","Short-term notes reduced from $8M to $3.5M; focus on paying down obligations.","Adimune progressing toward human trials; Pearsanta validating endometriosis and prostate cancer assays.","Pearsanta IPO uncertain due to weak market; timing depends on commercialization progress.","Company not at earnings stage; still raising capital; no near-term revenue or guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158617,"accession_number":"0001213900-25-045095","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["1.02","7.01","9.01"],"status":"ready","headline":"Aditxt terminates Appili acquisition; eliminates ~$16M closing obligations","event_type":"other_material","confidence":"high","bullets":["Termination of Arrangement Agreement with Appili effective May 31, 2025.","Originally announced April 2024 and amended multiple times.","Eliminates approximately $16M in closing obligations for Aditxt.","Aditxt still pursuing Evofem merger requiring ~$17M cash payments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158606,"accession_number":"0001213900-25-045098","cik":1726711,"company_name":"Aditxt, Inc.","ticker":"ADTX","form_type":"8-K/A","filed_at":"2025-05-19T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Aditxt files amendment with Evofem Q1 results; merger deadline extended to Sep 30, 2025","event_type":"other_material","confidence":"high","bullets":["Evofem Q1 2025 product sales net $845K, down 77% YoY from $3.6M; net income of $956K vs net loss $4.8M.","Fifth Amendment to merger agreement moves required close to Sep 30, 2025; Aditxt to invest $1.5M in April 2025.","Aditxt terminated Appili Therapeutics arrangement agreement effective May 31, 2025; removed from pro forma.","Evofem had working capital deficit of $65M, accumulated deficit $896.7M, and substantial doubt as going concern.","Evofem common stock moved from OTCQB to OTC Pink in April 2025 after failing minimum bid price compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}